Stockscreener 앱 받기
8.43
13.36%
-1.30
시간 외 거래:
8.42
-0.010
-0.12%
전일 마감가:
$9.73
열려 있는:
$9.74
하루 거래량:
592.44K
Relative Volume:
5.12
시가총액:
$145.52M
수익:
$3.25M
순이익/손실:
$-116.80M
주가수익비율:
-2.7639
EPS:
-3.05
순현금흐름:
$-98.17M
1주 성능:
+13.46%
1개월 성능:
+7.99%
6개월 성능:
-37.65%
1년 성능:
-63.54%
1일 변동 폭
$8.24
$9.84
1주일 범위
$7.04
$9.84
52주 변동 폭
$5.6652
$30.60
Rapt Therapeutics Inc Stock (RAPT) Company Profile
명칭
Rapt Therapeutics Inc
전화
(650) 489-9000
주소
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
RAPT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RAPT
Rapt Therapeutics Inc
|
8.43 | 145.52M | 3.25M | -116.80M | -98.17M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-22 | 재개 | H.C. Wainwright | Buy |
| 2024-12-26 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-11-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-11-11 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-11-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-05-14 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-05-10 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-05-10 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-02-22 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-02-21 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-02-21 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-02-21 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-02-20 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2024-02-16 | 개시 | Evercore ISI | Outperform |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-09-14 | 개시 | Berenberg | Buy |
| 2023-08-09 | 개시 | Stifel | Buy |
| 2023-06-15 | 개시 | Barclays | Overweight |
| 2023-01-04 | 개시 | Guggenheim | Buy |
| 2022-12-01 | 개시 | Goldman | Buy |
| 2022-09-21 | 개시 | CapitalOne | Overweight |
| 2022-05-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-12-09 | 개시 | JP Morgan | Overweight |
| 2021-08-12 | 개시 | SVB Leerink | Outperform |
| 2021-06-21 | 개시 | Piper Sandler | Overweight |
| 2020-06-01 | 개시 | H.C. Wainwright | Buy |
| 2020-05-19 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-04-13 | 개시 | ROTH Capital | Buy |
| 2019-11-25 | 개시 | BMO Capital Markets | Outperform |
| 2019-11-25 | 개시 | UBS | Buy |
| 2019-11-25 | 개시 | Wells Fargo | Outperform |
모두보기
Rapt Therapeutics Inc 주식(RAPT)의 최신 뉴스
Wall Street Analysts Predict a 282.65% Upside in Rapt Therapeutics (RAPT): Here's What You Should Know - Yahoo Finance
RAPT Therapeutics Executes 1-for-8 Reverse Stock Split - TipRanks
RAPT Therapeutics (RAPT) Trading Halted as News Awaits Release | RAPT Stock News - GuruFocus
Layoff Tracker: Gilead Cuts 36 Employees in California - BioSpace
Rapt Therapeutics announces effective date for 1-for-8 reverse stock split - Yahoo Finance
# RAPT Therapeutics to implement 1-for-8 reverse stock split By Investing.com - Investing.com South Africa
RAPT Finalizes Reverse Split Plan; 1-for-8 Ratio Effective June 16, 2025 - Nasdaq
RAPT Therapeutics Shares to Start Trading on a Split-Adjusted Basis Tuesday - marketscreener.com
RAPT Therapeutics Announces Effective Date For 1-For-8 Reverse Stock Split - MarketScreener
RAPT Therapeutics Announces Reverse Stock Split Effective June 2025 | RAPT Stock News - GuruFocus
# RAPT Therapeutics to implement 1-for-8 reverse stock split - Investing.com
RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split - GlobeNewswire
RAPT Therapeutics Announces Major Share Consolidation: 132M Shares Shrinking to 16.5M in Reverse Split - Stock Titan
Two Sigma Investments LP Sells 339,957 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
Transcript : RAPT Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 09 - MarketScreener
Rapt Therapeutics Get A Bullish Recommendation On ‘Significant Opportunity’ For Allergy Drug Candidate: Retail Worries About Cash Position - MSN
RAPT Therapeutics Announces Development Plans for RPT904 - TipRanks
Jane Street Group LLC Sells 29,821 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
Nuveen Asset Management LLC Buys 39,216 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
RAPT Therapeutics (RAPT) Has a New Rating from Clear Street - The Globe and Mail
Rapt Therapeutics Get A Bullish Recommendation On ‘Significant Opportunity’ For Allergy Drug Candidate: Retail Worries About Cash Position By Stocktwits - Investing.com India
Clear Street initiates Rapt Therapeutics stock with buy rating By Investing.com - Investing.com UK
Clear Street Initiates Coverage on Rapt Therapeutics (RAPT) with Buy Rating | RAPT Stock News - GuruFocus
Millennium Management LLC Sells 222,261 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
RAPT Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
RAPT Therapeutics Management to Share Latest Immunology Pipeline Updates at Major Healthcare Conferences - Stock Titan
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
RAPT Therapeutics Faces Nasdaq Delisting Notice - TipRanks
What is HC Wainwright’s Forecast for RAPT Q2 Earnings? - Defense World
UBS Group Cuts RAPT Therapeutics (NASDAQ:RAPT) Price Target to $1.00 - Defense World
RAPT Therapeutics (NASDAQ:RAPT) Stock Rating Upgraded by HC Wainwright - Defense World
D. E. Shaw & Co. Inc. Sells 278,173 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
RAPT Stock: HC Wainwright & Co. Announces New Price Target | RAP - GuruFocus
UBS Adjusts Price Target for Rapt Therapeutics (RAPT) | RAPT Stock News - GuruFocus
RAPT Analyst Update: UBS Adjusts Price Target to $1 | RAPT Stock News - GuruFocus
Rapt Therapeutics (RAPT) Receives Buy Rating with Promising Outl - GuruFocus
UBS Adjusts Price Target for Rapt Therapeutics (RAPT) | RAPT Sto - GuruFocus
Rapt Therapeutics (RAPT) Receives Buy Rating with Promising Outlook | RAPT Stock News - GuruFocus
UBS cuts Rapt Therapeutics stock target to $1 from $2 By Investing.com - Investing.com UK
Comerica Bank Purchases Shares of 58,040 RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
Dimensional Fund Advisors LP Sells 105,231 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
Rapt Therapeutics (RAPT) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Average Rating of “Hold” by Analysts - Defense World
RAPT Therapeutics Reports Improved Q1 2025 Results - TipRanks
RAPT Therapeutics Reports First Quarter 2025 Financial Results - GlobeNewswire
RAPT Therapeutics, Inc. SEC 10-Q Report - TradingView
RAPT Therapeutics Reports Third Quarter 2024 Financial Results - ADVFN
RAPT Therapeutics Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
RAPTRapt Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Renaissance Technologies LLC Has $584,000 Stock Position in RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
Rapt Therapeutics Inc (RAPT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.11%
1.70%
자본화:
|
볼륨(24시간):